Novavax

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 1.5K

Market Cap: $1.7B

Website

Introduction: Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Clinical Trials

Phase 3 Pivotal Trial of NanoFlu™ in Older Adults

Phase 3

Completed

Conditions: Influenza, Human

Interventions: Biological: NanoFlu
Biological: Fluzone Quadrivalent

First Posted Date: 2019-10-09

Last Posted Date: 2023-05-06

Lead Sponsor: Novavax

Target Recruit Count: 2654

Registration Number: NCT04120194

Locations: 🇺🇸
US045, Savannah, Georgia, United States
🇺🇸
US135, Hollywood, Florida, United States
🇺🇸
US025, Norfolk, Nebraska, United States

and more 16 locations

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

Phase 2

Terminated

Conditions: Influenza, Human

Interventions: Biological: NanoFlu (Quad-NIV)
Other: Matrix-M Adjuvant
Biological: Influenza Vaccine
Biological: Fluzone HD
Biological: Flublok Quadrivalent
Other: Placebo

First Posted Date: 2018-09-05

Last Posted Date: 2022-11-04

Lead Sponsor: Novavax

Target Recruit Count: 1375

Registration Number: NCT03658629

Locations: 🇺🇸
US137, Salisbury, North Carolina, United States
🇺🇸
US135, Hollywood, Florida, United States
🇺🇸
US045, Savannah, Georgia, United States

and more 11 locations

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: Fluzone HD - Day 0
Biological: NanoFlu
Biological: Fluzone HD - Day 21
Other: Saline - Day 21

First Posted Date: 2017-09-26

Last Posted Date: 2022-12-21

Lead Sponsor: Novavax

Target Recruit Count: 330

Registration Number: NCT03293498

Locations: 🇺🇸
Research Site US108, Raleigh, North Carolina, United States
🇺🇸
Research Site US106, Rocky Mount, North Carolina, United States
🇺🇸
Research Site US132, Statesville, North Carolina, United States

Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults

Phase 2

Completed

Conditions: Respiratory Syncytial Viruses

Interventions: Biological: RSV F Vaccine
Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant
Biological: Matrix-M1 Adjuvant
Other: Phosphate Buffer

First Posted Date: 2017-01-20

Last Posted Date: 2021-12-06

Lead Sponsor: Novavax

Target Recruit Count: 300

Registration Number: NCT03026348

Locations: 🇦🇺
Research Site AU006, Prahran, Victoria, Australia
🇦🇺
Resarch Site AU001, Nedlands, Western Australia, Australia
🇦🇺
Research Site AU005, Herston, Queensland, Australia

and more 2 locations

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

Phase 3

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSV F vaccine with adjuvant
Biological: Formulation buffer

First Posted Date: 2015-12-09

Last Posted Date: 2020-04-14

Lead Sponsor: Novavax

Target Recruit Count: 4636

Registration Number: NCT02624947

Locations: 🇺🇸
Research Site US095, Chicago, Illinois, United States
🇺🇸
Research Site US087, Johnson City, New York, United States
🇺🇸
Research Site US126, Alexandria, Louisiana, United States

and more 85 locations

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

Phase 3

Completed

Conditions: Respiratory Syncytial Virus (RSV)

Interventions: Biological: RSV-F Vaccine
Biological: Phosphate Buffer Placebo

First Posted Date: 2015-11-18

Last Posted Date: 2022-07-19

Lead Sponsor: Novavax

Target Recruit Count: 11850

Registration Number: NCT02608502

Locations: 🇺🇸
Research Site US062, Birmingham, Alabama, United States
🇺🇸
Research Site US061, Mobile, Alabama, United States
🇺🇸
Research Site US046, Mesa, Arizona, United States

and more 57 locations

Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.

Phase 2

Completed

Conditions: Respiratory Syncytial Virus (RSV)

Interventions: Biological: RSV-F Vaccine
Biological: Phosphate Buffer Placebo

First Posted Date: 2015-10-30

Last Posted Date: 2022-05-27

Lead Sponsor: Novavax

Target Recruit Count: 1330

Registration Number: NCT02593071

Locations: 🇺🇸
Rapid Medical Research, Cleveland, Ohio, United States
🇺🇸
Clinical Research Associates, Nashville, Tennessee, United States
🇺🇸
Group Health Research Institute, Seattle, Washington, United States

and more 7 locations

Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects

Phase 1

Completed

Conditions: Ebola

Interventions: Biological: Base Dose EBOV GP Vaccine
Biological: 2x Base Dose EBOV GP Vaccine
Biological: 8x Base Dose EBOV GP Vaccine
Biological: 4x Base Dose EBOV GP Vaccine
Biological: Placebo
Biological: Matrix-M Adjuvant

First Posted Date: 2015-02-25

Last Posted Date: 2021-11-24

Lead Sponsor: Novavax

Target Recruit Count: 230

Registration Number: NCT02370589

Locations: 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
🇦🇺
Q-Pharm Pty Ltd., Brisbane, Queensland, Australia
🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia

Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Comparator TIV
Biological: Quadrivalent VLP Vaccine

First Posted Date: 2014-12-04

Last Posted Date: 2016-09-23

Lead Sponsor: Novavax

Target Recruit Count: 400

Registration Number: NCT02307851

Locations: 🇺🇸
Miami Research Associates, Miami, Florida, United States
🇺🇸
Johnson County Clin Trials, Lenexa, Kansas, United States
🇺🇸
Clinical Trials of Texas, San Antonio, Texas, United States

and more 2 locations

A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age

Phase 1

Completed

Conditions: Respiratory Synctial Virus

Interventions: Biological: Hepatitis A Vaccine (0.5mL injection)
Biological: RSV F Vaccine with adjuvant (0.5mL injection)
Biological: RSV F Vaccine (0.5mL injection)
Biological: Placebo (0.5mL injection)

First Posted Date: 2014-11-20

Last Posted Date: 2016-04-28

Lead Sponsor: Novavax

Target Recruit Count: 32

Registration Number: NCT02296463

Locations: 🇨🇦
University of Calgary, Alberta Children's Hospital, Calgary, Alberta, Canada
🇨🇦
Dalhousie University, IWK Health Centre- Canadian Center for Vaccinology, Halifax, Nova Scotia, Canada
🇨🇦
Aggarwal and Associates, Brampton, Ontario, Canada

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy